Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Stock Market Today, 14 Oct: Sensex defends 82000, Nifty at 25145; all sectors in red
- Fintech revolution 2.0 is expected to unfold in India in the next 10 years: MobiKwik’s Upasana Taku
- DeepSeek to boost growth of India’s AI compute infra firms
- Why India has to plan a marathon and not a sprint in attracting global supply chains
